You are here

Article Text

Article menu
Download PDFPDF
Case Reports: Rare disease
Tumour-induced osteomalacia due to a durally-based intracranial phosphaturic mesenchymal tumour
  1. James Allan Douglas Shand1 and
  2. David Kim2
  1. 1Endocrinology and Diabetes, Waitemata District Health Board, Takapuna, New Zealand
  2. 2Endocrinology and Diabetes, Waitemata District Health Board, Auckland, New Zealand
  1. Correspondence to Dr James Allan Douglas Shand; jamesshand123{at}gmail.com

Abstract

A man in his 40s was referred with persistent hypophosphataemia and bony pain. A serum fibroblast growth factor 23 level was markedly elevated and a diagnosis of tumour-induced osteomalacia was considered. Whole body imaging revealed multiple insufficiency fractures but no osseus tumours. There was, however, a durally-based intracranial lesion whose imaging characteristics were consistent with a meningioma. The tumour was removed, leading to rapid normalisation of the patient’s symptoms and serum markers. Histology confirmed a phosphaturic mesenchymal tumour. We review the literature regarding this rare clinical situation.

  • Calcium and bone
  • Neuroendocrinology
  • Neuroimaging

https://doi.org/10.1136/bcr-2022-252412

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • Contributors DK was responsible for the conception of the case report. JADS generated the first draft. Both authors were involved in draft editing and agreed on the final manuscript.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Case reports provide a valuable learning resource for the scientific community and can indicate areas of interest for future research. They should not be used in isolation to guide treatment choices or public health policy.

    • Competing interests None declared.

    • Provenance and peer review Not commissioned; externally peer reviewed.